Everdrone
CPS 31Autonomous drones deliver emergency medical supplies and healthcare to patients, integrated into 911 response systems
Everdrone occupies a credible and defensible niche in emergency medical drone services with real operational deployments in Sweden and France, but remains a seed-stage company with unverified financials, minimal disclosed funding ($1.06M), and significant capital and regulatory scaling risks. The January 2026 board refresh signals intent to accelerate, but the company must prove it can convert pilot deployments into recurring, contracted revenue at scale before warranting a higher rating.
Operational deployments in both Sweden (VGR, Stockholm Ambulance) and France (Normandy DEMS) demonstrate real-world traction beyond lab or pilot stage, with integration into emergency dispatch chains
Focus on life-critical EMS missions (AED delivery, medical logistics) creates a high-barrier niche where safety certification, clinical integration, and public-sector trust are more defensible than hardware specs alone
January 2026 board refresh with expertise spanning aviation, healthcare, finance, and growth companies explicitly targets capital access, regulatory strategy, and market expansion — governance aligned with scaling needs
Appointment of Senior Medical Advisor (Jan 2026) and partnership with Stockholm Ambulance (Feb 2026) signal deepening clinical credibility and institutional relationships
Next-generation medical drone launch (Feb 2026) suggests continued R&D investment and product iteration, potentially improving mission capability and certification readiness
Reported 2024 revenue of ~€5.05M on seed funding, if verified, would indicate strong capital efficiency and meaningful public-sector contract traction
Total disclosed funding of only $1.06M seed is extremely low for scaling capital-intensive drone fleet operations across multiple countries — significant dilutive raises appear imminent
Reported €5.05M revenue from Tracxn aggregator has formatting inconsistencies and lacks primary verification; could reflect grants, in-kind contributions, or data errors rather than commercial revenue
Regulatory fragmentation across EU markets (BVLOS approvals, urban operations, payload constraints) could elongate sales cycles and constrain geographic expansion
No independently verified operational KPIs disclosed — mission counts, response times, clinical outcomes, safety incident rates, or mission success rates remain unknown
Competition from well-capitalized players (Wingcopter, Zipline, Matternet) expanding into medical logistics and from specialized peers (Redwing, Jedsy, Arone) could pressure pricing and market access
Small team (11-50 employees) may lack depth for simultaneous multi-country regulatory compliance, fleet operations, R&D, and commercial scaling
Capital insufficiency: $1.06M seed funding is inadequate for multi-country fleet scaling; failure to raise significant follow-on capital could stall expansion
Revenue verification: reported €5.05M revenue from third-party aggregator is unverified and may not reflect recurring commercial contracts
Regulatory risk: BVLOS and urban operations approvals are not documented in available sources; delays could block scaling in new markets
Competitive displacement: larger, better-funded drone logistics companies could enter EMS vertical with superior resources and established regulatory relationships
Concentration risk: heavy dependence on Swedish and French public-sector customers; loss of key contracts could materially impact operations
Technology risk: next-generation drone platform certifications and performance specifications remain undisclosed; airworthiness and detect-and-avoid capabilities unverified
Near-term capital raise: size, structure, and investor quality will signal institutional validation and provide runway for scaling
Multi-year service contracts with EMS/health authorities providing recurring revenue evidence
Documented BVLOS regulatory approvals enabling cross-border replication of operational model
Publication of operational KPIs (mission counts, response times, clinical outcomes) that validate the value proposition
Next-generation drone platform certification and performance disclosures